Back to today’s briefing

Story perspectives

FDA Approves Game-Changing HIV Treatment Amid Cost Concerns

6/24/2025

30 3

Summary

Story summary

The FDA has greenlit lenacapavir, known as Yeztugo, a groundbreaking injectable treatment for HIV prevention, administered just twice a year. Clinical trials revealed it nearly eradicates new infections in high-risk groups. However, its steep annual price of $28,218 raises concerns about accessibility, particularly for low-income communities. Gilead is committed to offering affordable solutions for those in need.

1 of 1

Story summary

The FDA has greenlit lenacapavir, known as Yeztugo, a groundbreaking injectable treatment for HIV prevention, administered just twice a year. Clinical trials revealed it nearly eradicates new infections in high-risk groups. However, its steep annual price of $28,218 raises concerns about accessibility, particularly for low-income communities. Gilead is committed to offering affordable solutions for those in need.